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Abstract: BACKGROUND Variability in standard-of-care classifications precludes accurate predictions
of early tumor recurrence for individual patients with meningioma, limiting the appropriate selection
of patients who would benefit from adjuvant radiotherapy to delay recurrence. We aimed to develop
an individualized prediction model of early recurrence risk combining clinical and molecular factors in
meningioma. METHODS DNA methylation profiles of clinically annotated tumor samples across mul-
tiple institutions were used to develop a methylome model of 5-year recurrence-free survival (RFS).
Subsequently, a 5-year meningioma recurrence score was generated using a nomogram that integrated
the methylome model with established prognostic clinical factors. Performance of both models was eval-
uated and compared with standard-of-care models using multiple independent cohorts. RESULTS The
methylome-based predictor of 5-year RFS performed favorably compared with a grade-based predictor
when tested using the 3 validation cohorts (ΔAUC = 0.10, 95% CI: 0.03-0.018) and was independently
associated with RFS after adjusting for histopathologic grade, extent of resection, and burden of copy
number alterations (hazard ratio 3.6, 95% CI: 1.8-7.2, P < 0.001). A nomogram combining the methy-
lome predictor with clinical factors demonstrated greater discrimination than a nomogram using clinical
factors alone in 2 independent validation cohorts (ΔAUC = 0.25, 95% CI: 0.22-0.27) and resulted in
2 groups with distinct recurrence patterns (hazard ratio 7.7, 95% CI: 5.3-11.1, P < 0.001) with clinical
implications. CONCLUSIONS The models developed and validated in this study provide important prog-
nostic information not captured by previously established clinical and molecular factors which could be
used to individualize decisions regarding postoperative therapeutic interventions, in particular whether
to treat patients with adjuvant radiotherapy versus observation alone.
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ABSTRACT	
Background:	Variability	in	standard-of-care	classifications	preclude	accurate	predictions	
of	early	tumor	recurrence	for	individual	patients	with	meningioma	limiting	the	appropriate	
selection	of	patients	who	would	benefit	from	adjuvant	radiotherapy	to	delay	recurrence.	
We	aimed	to	develop	an	individualized	prediction	model	of	early	recurrence	risk	
combining	clinical	and	molecular	factors	in	meningioma.		
Methods:	DNA	methylation	profiles	of	clinically-annotated	tumor	samples	across	multiple	
institutions	were	used	to	develop	a	methylome-model	of	5-year	recurrence-free-survival	
(RFS).	Subsequently,	a	5-year	meningioma	recurrence	score	was	generated	using	a	
nomogram	that	integrated	the	methylome-model	with	established	prognostic	clinical	
factors.	Performance	of	both	models	was	evaluated	and	compared	to	standard-of-care	
models	using	multiple	independent	cohorts.	
Results:	The	methylome-based	predictor	of	5-year	RFS	performed	favorably	compared	to	a	
grade-based	predictor	when	tested	using	the	three	validation	cohorts	(DAUC	=0.10,	95%CI	
0.03–0.018)	and	was	independently	associated	with	RFS	after	adjusting	for	
histopathological	grade,	extent	of	resection	and	burden	of	copy	number	alterations	(HR	3.6,	
95%CI	1.8–7.2,	P<0.001).	A	nomogram	combining	the	methylome-predictor	with	clinical	
factors	demonstrated	greater	discrimination	than	a	nomogram	using	clinical	factors	alone	
in	two	independent	validation	cohorts	(DAUC	=0.25,	95%CI	0.22	–	0.27)	and	resulted	in	
two	groups	with	distinct	recurrence	patterns	(HR	7.7,	95%CI	5.3–11.1,	P<0.001)	with	
clinical	implications.		
Conclusions:	The	models	developed	and	validated	in	this	study	provide	important	
prognostic	information	not	captured	by	previously	established	clinical	and	molecular	
 N-O-D-19-00019R1 
 4 
factors	which	could	be	used	to	individualize	decisions	regarding	post-operative	therapeutic	
interventions,	in	particular,	whether	to	treat	patients	with	adjuvant	radiotherapy	versus	
observation	alone	
	
Keywords:	methylation,	meningioma,	nomogram,	predictor,	recurrence	
	
Key	points:		
• Combining	DNA	methylation	with	clinical	factors	results	in	reliable	individualized	
estimations	of	recurrence	risk	
• Individualized	recurrence	risk	can	be	used	to	guide	post-operative	therapeutic	
interventions	
	
Importance	of	the	Study	
Our	work	is	the	first	to	demonstrate	the	transformative	utility	of	integrating	clinical	and	
molecular	factors	for	use	beyond	simple	classification	into	the	realm	of	individualized	
prognostication	for	any	brain	tumor.	Using	our	developed	and	validated	tools	that	are	
publicly	available,	clinicians	will	be	able	combine	clinical	and	molecular	factors	to	
determine	an	individualized	probability	of	recurrence	for	patients	with	meningiomas.	
This	represents	a	major	advance	in	the	field	of	personalized	medicine	for	neuro-oncology,	
and	the	use	of	this	tool	can	help	clinicians	overcome	one	of	the	most	challenging	limitations	
we	face	when	treating	patients	with	meningiomas.			
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INTRODUCTION	
Meningiomas	are	the	most	common	primary	intracranial	tumor.	They	account	for	37%	of	
all	central	nervous	system	tumors,	and	are	continuing	to	increase	in	incidence	with	the	
ageing	population1.	They	result	in	significant	neurological	morbidity	and	loss	of	quality	of	
life	by	exerting	mass	effect	on	critical	adjacent	brain	regions	1.	The	current	standard-of-
care	for	nearly	all	patients	with	symptomatic	meningiomas	includes	gross	total	tumor	
resection	with	removal	of	involved	dura	and	bone	when	possible2.	However,	despite	radical	
surgical	resection,	approximately	20%	of	meningiomas	display	aggressive	behaviour	with	
early	tumor	recurrence	resulting	in	a	clinical	course	of	repetitive	disease-	and	treatment-
related	morbidity.		Radiation	therapy	can	be	used	to	provide	disease	control	as	an	adjunct	
to	surgery	for	a	subset	of	tumors3,4.	However,	radiotherapy	can	often	result	in	adverse	
radiation	effects	that	lead	to	considerable	morbidity	and	neurological	dysfunction	long-
term	precluding	universal	use	in	all	patients5.	One	of	the	greatest	clinical	challenges	faced	
by	clinicians	is	the	inability	to	predict	early	tumor	recurrence	at	an	individual	patient	level	
which	limits	the	appropriate	selection	of	patients	who	would	benefit	from	adjuvant	
radiation	therapy.	
	
To	date,	the	most	reliable	clinical	factors	associated	with	recurrence	in	meningiomas	have	
been	the	World	Health	Organization	(WHO)	grade	of	the	tumor	and	extent	of	tumor	
resection	at	surgery2,6.	Although	both	are	crudely	associated	with	recurrence	rates	on	a	
population	level,	they	are	challenged	with	inter-rater	variability	of	grading	and	
considerable	within-grade	variation	of	recurrence	risk	for	individual	patients2,6.	In	the	past	
decade,	several	studies	have	focused	on	molecular	profiling	of	meningiomas	to	refine	
biological	subgroups7–13.		With	the	exception	of	mutations	in	BAP1	and	TERT	promoter,	
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each	of	which	occur	rarely	in	these	tumors,		the	mutations	identified	in	meningioma	have	
not	been	shown	to	be	tightly	correlated	to	patient	outcome	with	current	standard	of	care7–
10.		We	and	others	have	independently	shown	that	global	DNA	methylation	profiling	reveals	
robust	methylome-based	meningioma	subtypes,	however,	the	clinical	translation	of	this	to	
predict	recurrence	risk	for	individual	patients	has	not	been	demonstrated	to	date.	
	
To	examine	whether	methylation	profiles	can	be	defined	and	validated	for	clinical	utility,	
we	aimed	to	develop	and	validate	a	methylome-based	predictor	of	early	meningioma	
recurrence	that	could	be	combined	with	established	prognostic	clinical	factors	to	
individualize	decisions	regarding	the	need	for	post-operative	therapeutic	interventions,	in	
particular,	whether	to	treat	patients	with	adjuvant	radiation	therapy	versus	observation	
alone.	Our	work	is	the	first	in	neuro-oncology	to	demonstrate	the	transformative	utility	of	
integrating	clinical	and	molecular	factors	for	use	beyond	simple	classification	into	the	
realm	of	individualized	prognostication.	
	
MATERIALS	AND	METHODS	
Study	design	and	data	sources	
This	multicenter	retrospective	study	was	carried	out	in	accordance	with	individual	
institutional	ethics	and	review	board	guidelines	and	comprised	a	total	of	486	patients	with	
clinically	annotated	and	available	meningioma	samples.	Institutional	waivers	of	informed	
consent	were	obtained	due	to	minimal	patient	risk	associated	with	this	study.	Two-
hundred	and	eighty-two	(N=282)	fresh-frozen	or	formalin-fixed	paraffin	embedded	(FFPE)	
meningioma	tumor	samples	from	multiple	institutions	(N=76	from	Princess	Margaret	
Cancer	Research	Centre,	Toronto,	Canada;	N=206	from	European	centers	including	
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University	of	Heidelberg,	Heidelberg,	Germany	and	Goethe-University,	Frankfurt,	Germany	
and	University	of	Tubingen,	Tubingen,	Germany,	and	University	Hospital	Zurich,	Zurich,	
Switzerland	and	Medical	University	of	Vienna,	Vienna,	Austria)	comprised	the	discovery	
cohort.	which	was	split	into	a	training	cohort	(81%,	N=228	samples)	and	first	validation	
cohort	(19%,	N=54	samples)	each	balanced	for	tumor	grade,	tissue	type,	recurrence	status	
and	time	to	recurrence.	One	hundred	and	forty	(N=140)	FFPE	meningioma	tumor	samples	
from	a	separate	institution	(MD	Anderson	Cancer	Centre,	Houston,	USA)	were	used	as	a	
second	validation	cohort,	and	sixty-four	(N=64)	fresh	frozen	meningioma	tumor	samples	
from	two	other	institutions	were	used	as	a	third	validation	cohort	(N=46	from	Princess	
Margaret	Cancer	Research	Centre;	N=18	from	The	Chinese	University	of	Hong	Kong).	The	
sample	sets	from	Europe	and	MD	Anderson	comprised	the	subset	of	previously	published	
samples	for	which	clinical	data	(recurrence-free	survival	[RFS],	WHO	grade)	were	
available11,12.			Moreover,	TERT	promoter	mutation	status	was	available	on	a	subset	of	
previously	published	European	samples10,11.	Gene	expression	analysis	was	performed	on	
publicly	available	microarray	data	on	98	patients	with	meningiomas	of	all	grades	
(GSE1658114	and	GSE943815).	The	outline	for	the	overall	study	design	is	demonstrated	in	
Supplementary	Figure	S1.	
	
Definitions	
Hematoxylin	and	eosin	(H&E)	slides	for	each	patient	were	reviewed	for	meningioma	
diagnosis	and	WHO	grading	was	performed	according	to	the	current	WHO	2016	criteria	at	
local	institutions	by	experienced	neuropathologists.	Tumor	recurrence	and	time	to	
recurrence	were	the	primary	outcomes	of	interest	and	were	collected	locally	for	each	
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sample	as	previously	described11,12.	Briefly,	recurrence	was	defined	as	tumor	growth	
following	gross-total	resection	or	tumor	progression	following	subtotal	resection.	Time	to	
recurrence	was	determined	by	reviewing	post-operative	imaging	and	calculating	the	
duration	from	the	date	of	surgery	to	first	post-operative	imaging	documenting	tumor	
recurrence	in	concordance	with	documentation	in	the	medical	charts.	The	extent	of	
resection	(Simpson	grade2)	was	determined	based	on	the	surgeon’s	operative	report	in	
correlation	with	postoperative	cranial	imaging.	
	
Generation	of	an	individualized	methylome-predictor	of	5-year	RFS	
For	DNA	methylation	and	copy	number	analysis	of	the	samples,	DNA	was	extracted	from	
each	tumor	and	DNA	methylation	profiling	was	performed	using	Illumina	450k	
HumanMethylation	BeadChip	or	850k	EPIC	arrays	as	per	manufacturer	instructions	at	each	
institution.	Raw	data	files	(*.idat)	were	imported,	processed,	and	normalized	to	integrate	
data	from	multiple	generations	of	Infinium	methylation	arrays.	Copy	number	aberrations	
were	inferred	from	methylation	array	data16	and	burden	of	copy	number	alterations	was	
computed	per	sample	as	previously	described17.	Probes	that	were	common	in	both	450k	
HumanMethylation	Beadchip	and	850K	EPIC	arrays	were	selected	as	possible	features	for	
development	of	our	predictor	such	that	our	predictor	would	be	applicable	to	the	landscape	
of	available	technologies.	We	used	a	multi-step	strategy	to	select	the	probes	to	be	used	in	
the	generation	of	our	predictor	(See	Supplementary	Methods	and	Supplementary	Figure	
S2).		
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To	develop	the	methylome-based	predictor	of	early	meningioma	recurrence,	we	performed	
generalized	boosted	regression	modelling	using	the	final	selected	probes	in	samples	from	
the	training	cohort	to	predict	5-year	RFS.	Boosted	regression	modelling	using	WHO	grade	
as	a	sole	feature	in	the	training	cohort	was	also	performed	and	tested	in	each	validation	
cohort	to	compare	methylation-based	predictor	performance	to	a	standard-of-care	model.	
Performance	of	both	models	was	assessed	by	generating	time-dependent	receiver	
operating	characteristic	(ROC)	curves	and	computing	average	areas	under	the	ROC	curves	
(AUC)	for	each	validation	cohort	independently,	along	with	their	95%	confidence	intervals	
using	the	bootstrap	resampling	method	with	10,000	resamples18.			
	
Methylation	probe	annotation	was	performed	using	the	UCSC	Genome	Browse	
(GRCh38/hg38	assembly).	We	used	the	Functional	Annotation	Clustering	algorithm19	of	
Database	for	Annotation,	Visualization,	and	Integrated	Discovery	(DAVID)19	Bioinformatics	
Resource	6.8	to	identify	redundant	functional	clusters	represented	by	genes	annotated	
with	a	minimum	of	5	probes	(See	Supplementary	Figure	S3).	Two	publicly	available	
microarray	datasets	(GSE1658114	and	GSE943815)	reporting	on	22486	genes	for	98	
patients	with	meningiomas	were	pooled	to	correlate	methylation	data	with	gene	
expression	data	as	an	exploratory	analysis.	
	
Further	details	regarding	the	steps	for	generation,	validation	and	characterization	of	the	
methylome-predictor	of	5-year	RFS	can	be	found	in	Supplementary	Methods.	
	
Generation	of	a	meningioma-recurrence	score	
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To	create	a	contemporary	meningioma	recurrence	score	that	could	be	utilized	by	clinicians	
to	predict	early	risk	of	recurrence	for	individual	patients,	we	generated	a	nomogram	based	
on	a	Cox	model	that	incorporated	the	methylome-based	predictor,	WHO	grade,	and	extent	
of	resection	using	samples	from	the	training	cohort	and	second	validation	cohort	to	predict	
5-year	RFS.	Both	the	training	cohort	and	second	validation	cohort	were	used	to	train	this	
nomogram	in	order	to	increase	the	number	of	samples	available	to	capture	the	
heterogeneity	in	the	spectrum	of	data	available.	It	is	important	to	note	that	as	none	of	the	
samples	used	to	train	this	model	were	used	to	assess	model	performance	on	external	
validation.	The	global	performance	of	the	meningioma	recurrence	was	assessed	by	
generating	time-dependent	receiver	operating	characteristic	(ROC)	curves	and	computing	
average	area	under	the	ROC	curves	(AUC)	for	the	first	and	third	validation	cohort	
independently,	along	with	their	95%	confidence	intervals	using	the	bootstrap	resampling	
method	with	10,000	resamples18,20.	For	comparison,	a	nomogram	that	incorporated	only	
WHO	grade	and	extent	of	resection	as	the	sole	features	was	also	developed	in	similar	
fashion.	Internal	validation	using	bootstrap	resampling	using	10,000	resamples	was	also	
performed.	Model	calibration	was	assessed	visually	by	plotting	observed	event	rates	
against	nomogram	predicted	probabilities	for	two	risk	groups.	Detailed	descriptions	on	
nomogram	calculations	and	use	are	described	in	the	Supplementary	Methods	and	
Supplementary	Figure	S4.	
	
Statistical	analysis	
Summary	statistics	are	reported	as	counts	(and	proportions)	for	categorical	variables	and	
median	(and	range)	for	continuous	variables,	unless	otherwise	indicated.	Cohort	size	was	
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determined	by	availability	of	samples.	Statistical	analyses	were	performed	in	consultation	
with	two	expert	biostatisticians	(L.P	and	O.S).	
	
To	investigate	the	clinical	relevance	of	the	methylome-based	predictor	and	meningioma	
recurrence	score,	distribution	of	survival	times	was	performed	using	Kaplan-Meier	
methods	and	compared	across	groups	using	log-rank	testing.	The	frequency	of	genome-
wide	copy	number	alterations	across	groups	was	computed	and	plotted	using	a	custom	
algorithm.	The	performance	of	a	methylome-based	predictor	was	compared	to	grade-based	
predictor	by	computing	an	average	DAUC	(AUCmethylome	-	AUCgrade)	and	95%CI	from	all	
bootstraps	and	the	performance	of	the	meningioma	recurrence	score	incorporating	the	
methylome	predictor	was	compared	to	a	nomogram	excluding	the	methylome	predictor	by	
computing	average	DAUC	(AUCcombined	nomogram	–	AUCclinical	only	nomogram)	and	95%CI	in	similar	
fashion.		
	
Hazard	ratios,	including	95%	confidence	intervals	(CI),	were	calculated	based	on	
univariable	and	multivariable	Cox	regression	modeling	for	the	methylome-based	predictor	
and	other	covariates	including	WHO	grade,	extent	of	resection,	and	burden	of	copy	number	
alterations.	Proportional	hazards	assumption	was	tested	by	computing	Schoenfeld	
residuals	for	each	covariate	and	testing	was	performed	according	to	Grambsch	and	
Therneau21	(Supplementary	Figure	S5	and	Supplementary	Table	S1).	Martingale	residuals	
were	plotted	against	methylation	predictor	probabilities	to	determine	appropriateness	of	
linear	modeling	(Supplementary	Figure	S6).	Sensitivity	analyses	evaluating	the	possible	
confounding	effects	of	TERT	promoter	mutations,	receipt	of	adjuvant	radiation	therapy,	
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and	center-effects	were	performed	using	multivariable	Cox	regression	in	samples	with	
available	information.	Comparison	of	proportions	across	groups	was	completed	using	c2	
test	and	Fisher	Exact	test,	where	appropriate.	
	
Two-sided	p-values	are	reported,	and	the	threshold	for	statistical	significance	was	set	a	
priori	at	a=	0.05.	We	used	R	version	3.3.1	for	all	statistical	analyses,	model	generation,	and	
model	validation.	
	
RESULTS	
A	set	of	9529	probes	were	selected	from	an	initial	training	cohort	and	generalized	boosted	
regression	modeling	was	performed	to	develop	a	DNA	methylation-based	predictor	of	5-
year	recurrence	risk	in	meningioma	(Supplementary	Figure	S1).		Three	validation	cohorts	
(Supplementary	Table	S2)	were	used	to	test	the	performance	of	the	methylation-based	
predictor	compared	to	a	grade-based	predictor.	
	
Validation	of	a	methylome-predictor	of	early	meningioma	recurrence	
The	methylome-based	predictor	performed	favorably	compared	to	the	grade-based	
predictor	at	5-years	in	each	of	the	3	validation	cohorts	(Figure	1)	with	substantial	
statistical	improvements	in	performance	when	tested	in	all	combined	validation	cohorts	
(DAUC	=	0.10,	95%CI	0.03	–	0.18).	When	stratified	by	median,	the	5-year	methylome-
predictor	distinguished	risk	groups	(lower	and	higher	risk)	in	all	3	validation	cohorts	
(Figure	2).	Patients	in	the	higher	risk	group	had	a	median	RFS	of	2.1	years,	8.1	years,	and	
4.2	years	in	the	first,	second,	and	third	validation	cohorts	respectively	compared	to	patients	
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in	the	lower	risk	groups	which	had	median	RFS	of	“unreached”	in	the	first	and	second	
validation	cohorts	and	median	RFS	of	7.2	years	in	the	third	validation	cohort	(HR	8.1	
95%CI	2.8	–	23.8,	HR	3.5	95%CI	1.8	–	6.6,	and	HR	2.0,	95%CI	1.2	–	3.7,	respectively).		
	
DNA	copy	number	analysis	demonstrated	that	increased	frequency	of	copy	number	
aberrations	in	the	higher	risk	groups,	as	demonstrated	by	high	proportion	of	chromosomal	
deletions	in	1p,	4p,	6q,	10q,	14q,	and	18q	(Figure	3).	The	total	burden	of	copy	number	
alterations	was	also	correlated	with	risk	groups,	with	greatest	proportion	of	burden	of	
copy	number	alterations	found	in	the	higher	risk	groups	in	all	three	validation	cohorts	
(Supplementary	03).	It	is	noteworthy	that	of	all	patients	with	high	burden	of	copy	number	
aberrations	from	all	three	validation	cohorts,	only	12	patients	(4.6%)	were	in	the	lower	
risk	group.	
	
Multivariable	Cox	regression	analysis	demonstrated	that	the	5-year	methylome	based	
predictor	was	independently	associated	with	RFS	in	samples	from	all	validation	cohorts	
(HR	3.6,	95%CI	1.8	–	7.2,	P	<	0.001)	after	controlling	for	tumor	grade,	extent	of	resection,	
burden	of	copy	number	alterations	(Table	S4).		Sensitivity	analyses	including	receipt	of	
adjuvant	therapy,	TERT	promoter	mutations,	and	center	of	treatment	as	covariates	did	not	
alter	this	relationship	and	these	covariates	were	not	independently	associated	with	RFS	
(Supplementary	Tables	S5-7).		
	
Current	clinical	practice	relies	on	histopathologic	grade	to	inform	the	decision	of	post-
surgical	management	of	meningioma.		Patients	with	grade	I	tumors	are	most	commonly	
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monitored	with	serial	imaging	after	surgery,	while	patients	with	grade	II	and	III	tumors	are	
considered	for	adjuvant	therapy,	such	as	radiation,	to	prevent	recurrence.		There	is,	
however,	unexplained	clinical	variability	in	RFS	within	all	grades	of	meningioma,	and	we	
examined	the	use	of	the	5-year	methylome-predictor	to	address	this	issue.		Among	patients	
with	WHO	grade	II	tumors	in	all	validation	cohorts,	the	median	RFS	for	the	higher	risk	
group	was	2.6	years	compared	to	a	median	RFS	of	8.4	years	in	the	lower	risk	group	(HR	2.8,	
95%CI	1.7	–	4.8,	P	<	0.001,	Figure	4B).	Patients	with	WHO	Grade	I	tumors	in	all	validation	
cohorts	also	had	increased	risk	for	recurrence	in	the	higher	risk	group	(HR	2.9,	95%CI	1.3	–	
6.6,	P=0.006,	Figure	4A)	with	only	3	patients	in	the	lower	risk	group	recurring	within	the	
first	5	years	compared	to	18	patients	in	the	higher	risk	group.	Lastly,	patients	with	WHO	
Grade	III	tumors	from	all	validation	cohorts	had	poor	median	RFS	in	the	higher	risk	group	
(1.3	years),	compared	to	a	median	RFS	of	6.0	years	in	the	lower	risk	group	(HR	3.0,	95%CI	
1.4	–	6.5,	P=0.004,	Figure	4C).	
	
Characterization	of	predictor	CpG	sites	
The	selected	9529	probes	used	in	our	model	comprise	only	1%	of	all	probes	included	on	
the	850K	Illumina	Array.	These	probes	were	enriched	to	be	found	in	the	promoter	regions	
(N=3057,	32.1%)	and	located	on	CpG	islands	(N	=	4633,	48.6%)	compared	to	all	probes	
found	on	the	850K	Illumina	Array	(29.6%,	P	<	0.001	and	18.0%,	P	<	0.001,	respectively;	
Supplementary	Table	S8)	Of	the	9529	probes,	only	1261	(13.2%)	were	“favorable”	probes	
associated	with	lower	risk	of	recurrence	when	methylated	(HR	ranging	from	0.002	to	0.38,	
on	univariable	Cox	regression	with	associated	P	<	0.001).	The	remaining	8237	(86.8%)	
probes	were	“unfavorable”	probes	associated	with	higher	risk	of	recurrence	when	
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methylated	(HR	ranging	from	2.45	to	517.82,	on	univariable	Cox	regression	with	associated	
P	<	0.001).	
	
There	were	2332	probes	annotated	to	294	genes	with	at	least	5	probes	represented	per	
gene.	Of	these	(Supplementary	Table	S9),	only	68	of	2332	probes	(2.9%)	were	found	to	be	
“favorable”	probes	(associated	with	lower	recurrence	risk	when	methylated,	HR	ranging	
from	0.008	to	0.252	on	univariable	Cox	regression	with	associated	P	<	0.001).	The	
remaining	2265	probes	(97.1%)	were	found	to	be	“unfavorable”	probes	associated	with	
greater	recurrence	risk	(associated	with	higher	recurrence	risk	when	methylated,	HR	
ranging	from	2.95	to	517.82	on	univariable	Cox	regression	with	associated	P	<	0.001).	
Functional	annotation	clustering	of	these	2265	“unfavorable”	probes	revealed	that	
homeobox	(enrichment	score	=	54.33)	and	TBox	(enrichment	score	=	4.12)	were	highly	
significant	redundant	functional	clusters	(Supplementary	Figure	S3).	Gene	expression	
analysis	of	Homeobox	family	of	genes	and	Tbox	genes	for	which	methylation	data	was	also	
available,	demonstrated	that	although	these	genes	were	relatively	hypermethylated	in	
recurrence-prone	tumors,	they	were	either	upregulated	or	non-differentially	expressed	
(Supplementary	Table	S10).	
	
Validation	and	clinical	utility	of	a	meningioma	recurrence	score	
To	generate	and	validate	a	meningioma	recurrence	score	that	could	be	translated	to	the	
clinic,	we	developed	a	nomogram	to	predict	5-year	RFS	that	incorporated	the	validated	5y	
methylome-based	predictor	with	established	prognostic	covariates	(WHO	grade,	and	
extent	of	resection)	using	samples	from	the	training	cohort	and	second	validation	cohort	
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(Figure	5).	Validation	of	the	nomogram	using	the	first	validation	cohort	and	third	
validation	cohort	independently	as	well	as	both	validation	cohorts	combined	demonstrated	
greater	predictive	performance	of	the	nomogram	with	methylome	predictor	included	
compared	to	a	nomogram	using	clinical	factors	(WHO	grade	and	extent	of	resection)	alone	
(DAUC	=	0.24,	95%CI	0.19	–	0.28;	DAUC	=	0.26,	95%CI	0.22	–	0.31;	DAUC	=	0.25,	95%CI	
0.22	–	0.27	respectively,	Figure	5).	The	discriminative	power	of	the	meningioma	recurrence	
score	was	approximately	82%	in	combined	validation	cohorts	(AUC	=	0.82,	95%CI	0.76	–	
0.87).	The	performance	of	the	model	using	external	validation	and	internal	validation	
approaches	were	similar	(Supplementary	Figure	S7).	The	highest	proportion	of	allottable	
points	given	in	the	nomogram	is	based	on	probabilities	from	the	methylome-based	
predictor,	again	suggesting	that	the	methylome-predictor	has	greater	importance	in	
determining	recurrence	risk	in	meningiomas	compared	to	established	clinical	factors.	
Calibration	and	Kaplan-Meier	survival	analysis	of	the	meningioma	recurrence	score	clearly	
stratifies	patients	with	high	risk	and	low	risk	for	5-year	recurrence	(HR	7.7,	95%CI	5.3	–	
11.1,	P	<	0.001,	Figure	6).		Interestingly,	while	histologic	grades	II	and	III	are	meant	to	
predict	high	recurrence	risk,	we	find	that	the	low-risk	group	in	total	contains	39	grade	II	
tumors	(34.5%	of	the	grade	II	tumors)	and	4	grade	III	tumors	(8.3%	of	the	grade	III	
tumors).	Conversely,	while	a	WHO	grade	I	designation	is	meant	to	convey	a	low	risk	of	
recurrence,	there	were	35	(21.2%)	patients	with	grade	I	tumors	in	the	high-risk	group.	
These	results	indicate	refinement	of	risk	estimate	by	the	nomogram	relative	to	current	
classification	standards.		To	facilitate	unrestricted	global	dissemination,	we	have	created	a	
freely	available	online	calculator	of	the	meningioma	recurrence	score	
https://meningiomas.shinyapps.io/meningioma_recurrence_score_online_calculator/.		
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Details	on	imputations	for	the	online	calculator	can	be	found	in	the	Supplementary	
Methods,	and	case	examples	demonstrating	the	power	of	personalized	predictions	are	
detailed	in	Supplementary	Figures	S8-10.	
	
DISCUSSION		
	
In	this	multicenter	study,	we	demonstrated	the	transformative	utility	of	integrating	clinical	
and	molecular	factors	for	use	beyond	simple	classification	into	the	realm	of	individualized	
prognostication	in	neuro-oncology.	Our	methylome-based	predictor	was	more	reliably	able	
to	predict	early	(5-year)	recurrence-free	survival	in	comparison	with	histologic	grading	
and	was	associated	with	RFS	independent	of	established	clinical	and	molecular	factors.		
Combining	the	methylome	predictor	with	established	prognostic	clinical	factors	(WHO	
grade	and	extent	of	resection)	in	a	meningioma	recurrence	score	refined	prognostication	
for	individual	patients	with	meningiomas	beyond	established	prognostic	clinical	and	
molecular	factors	with	therapeutic	implications	for	individualizing	decision-making	
regarding	the	need	for	adjuvant	therapy	after	surgery	in	meningiomas.		
	
Although	WHO	grade	is	associated	with	recurrence	in	populations	of	meningioma	patients,	
and	is	currently	used	to	guide	therapy,	the	clear	within-grade	variation	for	risk	of	
recurrence	and	inter-rater	variability	makes	it	challenging	to	rely	on	tumor	grade	alone	to	
predict	recurrence	and	guide	postoperative	management	decisions	for	individual	patients.		
As	a	manifestation	of	this	imprecision,	some	patients	with	biologically	aggressive	tumors	
may	be	inappropriately	subsumed	in	within	the	group	of	histologically	benign	tumors.		
With	current	standard	of	care,	it	is	thought	that	up-front	treatment	with	adjuvant	radiation	
therapy	after	surgical	resection	offers	the	best	chance	to	delay	recurrence,	and	therefore	
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some	patients	are	not	appropriately	selected	for	adjuvant	treatment	with	standard-of-care	
approaches3,4.	Conversely,	there	are	also	some	patients	with	histologically	defined	
intermediate	or	higher-grade	tumors	that	in	fact	harbor	indolent	tumor	behavior.		Such	
patients	may	be	receiving	adjuvant	radiation	therapy	in	the	absence	of	a	defined	need.	
Radiation,	even	when	optimized	to	minimize	adverse	effects,	still	carries	the	risk	for	
adverse	radiation	effects	such	as	reactive	inflammation,	vasculitis,	and	necrosis,	all	of	
which	have	sequelae	on	patient	cognition	and	quality	of	life5.	There	is	a	clear	need	for	a	
more	refined	predictor	of	recurrence	patterns	for	individual	patients	with	meningiomas	
beyond	simple	classifications,	so	that	the	decision	for	adjuvant	therapy,	radiotherapy	or	
otherwise,	can	be	appropriately	selected	and	personalized	for	patients.			
	
The	burden	of	chromosomal	alterations	have	repeatedly	been	shown	to	be	one	of	the	most	
important	prognostic	molecular	alterations	in	meningioma11,17,22.	Similar	to	others11,22,	we	
found	recurrent	alterations	in	1p,	4p,	6q,	10q,	14q,	and	18q	in	a	subset	of	meningiomas	that	
were	enriched	in	higher	risk	group.		However,	using	a	previously	published	copy	number	
score	designed	to	identify	meningiomas	with	high	recurrence	risk17,	we	found	that	the	
burden	of	copy	number	alteration	was	not	an	independent	predictor	of	recurrence	once	
adjusted	for	methylation	signature.	Similarly,	although	TERT	promoter	mutations	are	
known	to	be	enriched	in	more	aggressive	meningiomas10,	our	analysis	demonstrated	that	
TERT	promoter	mutation	was	not	independently	associated	with	RFS	on	multivariable	
analysis	with	the	5-year	methylome	predictor	included	in	the	model.	Taken	together,	these	
results	suggest	that	our	5-year	methylome	predictor	can	provide	prognostic	information	
beyond	previously	established	molecular	factors	in	meningioma.	
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Probes	included	in	the	predictor	were	selected	based	on	correlations	of	either	hypo-	or	
hypermethylated	status	with	respect	to	RFS.		Interestingly,	the	distribution	of	these	probes	
was	not	random,	either	with	respect	to	methylation	status	nor	with	respect	to	association	
with	known	genes.		The	majority	(over	86%)	of	our	included	probes	were	all	associated	
with	unfavorable	RFS	when	hypermethylated.	This	suggests	that	in	general,	
hypermethylation	of	a	set	of	CpG	sites	in	meningioma	correlates	with	clinical	
aggressiveness.	For	example,	hypermethylation	of	the	homeobox	and	Tbox	families	of	
genes	were	found	to	be	highly	overrepresented	in	the	set	of	relevant	probes,	suggesting	
possible	involvement	of	this	class	of	developmental	factors	in	the	clinical	behavior	of	
meningioma,	which	requires	further	validation.	
	
To	generate	a	tool	that	could	be	used	by	clinicians	to	capture	the	heterogeneity	in	
recurrence	risk	in	meningiomas,	we	established	a	5-year	meningioma	recurrence	score	
that	combined	our	validated	methylome-based	predictor	with	well-established	prognostic	
clinical	factors	(WHO	grade	and	extent	of	resection).	The	performance	of	our	meningioma	
recurrence	score	was	improved	with	the	methylome-based	predictor	included	in	the	
nomogram	(DAUC	=	0.25,	95%CI	0.22	–	0.27),	and	the	overall	discrimination	of	our	
nomogram	was	high	(AUC	approximately	82%	in	two	independent	cohorts).	The	
construction,	and	evaluation,	of	our	nomogram	meets	the	standards	of	reporting	on	
nomograms	in	oncology	and	is	one	of	few	to	demonstrate	robust	evaluation	using	multiple	
independent	validation	cohorts23.	Now	that	we	have	demonstrated	that	our	tools	are	
robustly	validated,	we	are	well	positioned	to	prospectively	validate	the	use	of	our	tools	to	
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demonstrate	efficacy	with	adjuvant	therapy	strategies	in	high-risk	patients24.	Our	
meningioma	recurrence	score	informs	both	patients	and	clinicians	about	individualized	
risk	of	recurrence,	can	be	used	to	guide	clinicians	regarding	the	need	for	adjuvant	therapy	
and/or	close	clinical	follow-up.			
	
Our	study	has	some	limitations.	First,	although	we	have	identified	a	group	of	probes	with	
distinct	epigenetic	changes	that	in	combination	are	predictive	of	recurrence	risk	in	
meningiomas	for	individual	patients,	it	is	unclear	whether	these	changes	may	be	conferring	
variant	behavioural	phenotypes	or	whether	they	are	a	surrogate	for	general	cellular	
dysregulation.	Nevertheless,	the	set	of	highly	refined	and	selected	probes	in	our	predictor	
are	enriched	to	be	located	on	promotors	of	CpG	islands	where	aberrant	DNA	methylation	
has	clearly	been	linked	to	carcinogenesis25.	The	correlation	of	methylation	with	gene	
expression	in	our	study	was	exploratory	and	would	benefit	from	additional	investigation	
with	matched	epigenetic	and	transcriptomic	analysis	in	the	same	samples.	Moreover,	
although	each	institution	conformed	to	a	common	definition	for	tumour	recurrence	and	
time	to	recurrence,	there	is	no	universally	standardized	definition	of	recurrence	in	
meningiomas.	The	Response	Assessment	in	Neuro-Oncology	guidelines	may	offer	an	
avenue	for	standardized	definition	of	recurrence	to	be	collected	on	meningiomas	in	future	
clinical	trials,	which	will	help	with	communication	across	different	centres	and	may	also	
help	with	further	model	refinement26.	
	
Our	predictor	has	been	designed	and	validated	such	that	it	can	be	applied	to	data	from	
fresh	frozen	or	paraffin	embedded	tissues	using	the	current	commonly-used	standard	
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platform	for	genome-wide	DNA	methylation	profiling,	facilitating	immediate	adoption	into	
clinical	practice.		Our	newly	developed	and	retrospectively	validated	meningioma	
recurrence	score	combines	both	methylome	and	clinical	factors	and	can	be	freely	used	by	
clinicians	to	personalize	decision	making	regarding	post-operative	management	of	the	
most	common	primary	intracranial	brain	tumor	via	a	web-based	interface.	
	
DATA		ACCESSION:	Previously	unpublished	raw	methylation	files	(idat	files)	have	been	
submitted	to	the	European	Genome-phenome	Archive	(EGAS00001003490).	
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FIGURE	LEGENDS	
	
Figure	1.	Comparison	of	grade-based	and	methylome-based	recurrence-free	survival	
predictor	performance.	Data	presented	are	time-dependent	receiver	operating	
characteristic	curve	(ROC)	and	average	area	under	the	curve	(AUC)	as	well	as	DAUC	
(DAUC)	with	95%CI	using	10,000	bootstrap	resampling	validation	approach	for	
methylome-based	and	grade-based	predictors	in	the	(A)	first	validation	cohort	and	(B)	
second	validation	cohort	(C)	third	validation	cohort,	(D)	combined	validation	cohorts.	
	
Figure	2.	Recurrence-free	survival	(RFS)	analysis	of	the	first	validation	cohort	(A),	second	
validation	cohort	(B),	and	(C)	third	validation	cohort	using	the	5y	methylome-based	RFS	
predictor,	based	on	separation	into	distinct	risk	groups	by	median.	
	
Figure	3.	Frequency	of	copy	number	alterations	across	the	genome	stratified	in	risk	groups	
according	to	the	methylome-based	predictor.	Groups	correspond	to	same	groups	seen	in	
Figure	2.	
	
Figure	4.	Recurrence-free	survival	(RFS)	analysis	of	all	WHO	grade	I	(A),	WHO	grade	II	(B)	
and	WHO	grade	III	(C)	tumors	in	all	three	validation	cohorts.		
	
Figure	5.	Nomogram	to	predict	5-year	recurrence	risk	in	meningiomas	(A)	Total	points	
generated	from	scoring	of	methylome-based	RFS	predictor,	WHO	grade,	and	Simpson	grade	
are	tallied	in	the	calculator	and	correlated	to	5-year	RFS	in	the	nomogram	in	the	Risk	
 N-O-D-19-00019R1 
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Nomogram.	(B)	Time-dependent	average	AUC	with	95%CI		as	well	as	DAUC	(DAUC)	with	
95%CI	using	10,000	bootstrap	resampling	validation	approach	generated	for	the	
meningioma	recurrence	score	and	a	nomogram	using	clinical	factors	alone	in	the	first	and	
third	validation	cohorts	as	well	as	both	combined	validation	cohorts.	(C)	Calibration	curve	
of	the	nomogram	to	predict	recurrence-free	survival	at	5	years	in	the	combined	validation	
cohort.	The	observed	recurrence-free	survival	is	plotted	on	the	y-axis	and	nomogram	
predicted	probability	is	plotted	on	the	x-axis.		
	
Figure	6.	The	meningioma	recurrence	score	identifies	two	risk	groups	(high	risk	versus	low	
risk)	that	may	help	individualize	adjuvant	management	decisions	such	as	the	need	for	
radiation	therapy	in	patients	with	meningiomas.	Patient	tumor	samples	can	be	
interrogated	for	DNA	methylation	profile	of	selected	9529	probes	and	a	5-year	methylome-
based	RFS	predictor	score	is	generated.	This	score	is	combined	with	tumor	WHO	grade	and	
Simpson	grade	in	the	meningioma	recurrence	score	to	develop	an	individualized	
probability	of	5-year	recurrence-free	survival.		
	
	
	
	
	
	
	






